Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
CH Liu, JH Kao - Hepatology International, 2022 - Springer
Hepatitis C virus (HCV) infection is a major health problem with significant clinical and
economic burdens in patients with chronic kidney disease (CKD) stage 4 or 5. Current …
economic burdens in patients with chronic kidney disease (CKD) stage 4 or 5. Current …
[HTML][HTML] A systematic review of direct-acting antivirals for hepatitis C in advanced CKD
Introduction Direct-acting antivirals (DAAs) have improved treatment of hepatitis C virus
(HCV) infection in patients with chronic kidney disease (CKD). To facilitate the 2022 update …
(HCV) infection in patients with chronic kidney disease (CKD). To facilitate the 2022 update …
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
CH Liu, CY Chen, WW Su, KC Tseng, CC Lo, CJ Liu… - Gut, 2022 - gut.bmj.com
Objective Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir
(SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus …
(SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus …
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis
Abstract Background & Aims There is emerging data on the use of Sofosbuvir‐based directly
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage …
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage …
Management of hepatitis c virus and hepatitis b virus infection in the setting of kidney disease
Treatment of chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection poses
unique challenges in patients with kidney disease. Direct-acting antivirals have been a …
unique challenges in patients with kidney disease. Direct-acting antivirals have been a …
The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
R Chen, Y Xiong, Y Zeng, X Wang, Y Xiao… - Frontiers in Public …, 2023 - frontiersin.org
Background Hepatitis C virus (HCV) infection is an independent risk factor associated with
adverse outcomes in patients with end-stage renal disease (ESRD). Due to the wide variety …
adverse outcomes in patients with end-stage renal disease (ESRD). Due to the wide variety …
Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
F Fabrizi, F Tripodi, R Cerutti, L Nardelli, CM Alfieri… - Viruses, 2022 - mdpi.com
Background: Hepatitis C virus (HCV) is still common in patients with chronic kidney disease.
It has been recently discovered that chronic HCV is a risk factor for increased incidence of …
It has been recently discovered that chronic HCV is a risk factor for increased incidence of …
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis
F Shehadeh, M Kalligeros, K Byrd, D Shemin… - Scientific reports, 2020 - nature.com
Hepatitis C virus (HCV) infection among maintenance hemodialysis patients is implicated in
increased morbidity and mortality compared to uninfected patients. Sofosbuvir (SOF)-based …
increased morbidity and mortality compared to uninfected patients. Sofosbuvir (SOF)-based …
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic …
Introduction Sofosbuvir (SOF) and velpatasvir (VEL) is a pan‐genotypic regimen for the
treatment of Hepatitis C virus (HCV) infection. The data on the efficacy and safety of this …
treatment of Hepatitis C virus (HCV) infection. The data on the efficacy and safety of this …
An updated view on the antiviral therapy of hepatitis C in chronic kidney disease
F Fabrizi, R Cerutti, P Messa - Pathogens, 2021 - mdpi.com
Background: Hepatitis C virus infection remains common in patients with chronic kidney
disease, including those on maintenance dialysis. The relationship between hepatitis C …
disease, including those on maintenance dialysis. The relationship between hepatitis C …